Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 2680 in Narcolepsy Type 1
NCT06358950Phase 2Completed
- Sponsor
- Alkermes
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of alixorexton in narcolepsy type 1 (NT1), sponsored by Alkermes. Started Mar 2024; status: completed.
02
Drugs
alixorexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT06358950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06358950.